200 Participants Needed

Neuromodulation + Neurorehabilitation for Concussion + PTSD

Recruiting at 2 trial locations
CM
AG
Overseen ByAnn Guernon, MS
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a combination treatment for individuals experiencing attention issues after a mild traumatic brain injury (mTBI), with or without PTSD. It combines computer-based attention training (APT) and magnetic stimulation (iTBS, or Intermittent Theta Burst Stimulation) to evaluate their effectiveness in improving attention problems. Participants will join one of four groups, each testing different combinations of these treatments to determine the most effective approach. Eligible participants have experienced mTBI for at least three months and face attention challenges in daily life. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could enhance attention treatments for mTBI patients.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as CNS stimulants, during participation. If your mental health medication dosage has changed in the last 30 days, you may not be eligible. Please consult with the trial team for specific guidance on your medications.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that Attention Process Training (APT) is safe and well-tolerated. It improves attention skills after brain injuries, such as concussions, without causing significant side effects.

Intermittent theta burst stimulation (iTBS) is also safe. It effectively treats conditions like PTSD and depression by using short magnetic pulses to stimulate the brain. Studies report no major safety concerns, and participants usually handle the treatment well.

Both APT and iTBS have strong safety records. For those considering joining a trial, these treatments have been studied and found to be safe.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they combine neuromodulation and cognitive training to tackle concussion and PTSD in a new way. Unlike standard treatments that often focus on medication or traditional therapy, this approach uses intermittent theta-burst stimulation (iTBS) targeting the brain's dorsolateral prefrontal cortex, potentially enhancing brain plasticity and cognitive function. Additionally, the Attention Process Training (APT) program offers a novel computer-based cognitive training experience. Together, these treatments could offer faster and more effective relief from symptoms by directly engaging and retraining the brain's pathways.

What evidence suggests that this trial's treatments could be effective for concussion and PTSD?

Research has shown that both APT (Attention Process Training) and iTBS (intermittent theta-burst stimulation) hold promise for alleviating symptoms of mild traumatic brain injury (mTBI) and PTSD (post-traumatic stress disorder). APT has successfully improved attention and cognitive skills in individuals with brain injuries, regardless of the injury's severity or timing. iTBS, meanwhile, quickly alleviates PTSD symptoms and has demonstrated positive effects on depression. In this trial, participants will be assigned to different treatment arms to evaluate these therapies' effects. Some will receive real APT combined with real iTBS, while others will receive placebo versions of one or both treatments. Early evidence suggests that combining these therapies could significantly enhance attention and cognitive skills.36789

Who Is on the Research Team?

TL

Theresa LB Pape, Dr.PH

Principal Investigator

Northwestern University

Are You a Good Fit for This Trial?

This trial is for adults aged 18-60 who have experienced a mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) between 3 months to 10 years ago. Candidates must be fluent in English, not involved in other studies, without epilepsy or severe heart conditions, not pregnant, and free from certain metal implants that affect MRI or TMS procedures.

Inclusion Criteria

You have both a head injury and post-traumatic stress disorder, as determined by specific medical assessments.
I experienced a mild traumatic brain injury between 3 months and 10 years ago.

Exclusion Criteria

You scored less than 85% on a test that checks if you are answering questions honestly, and a specialist thinks you might not be answering accurately.
You have a pacemaker, defibrillator, cochlear implant, nerve stimulator, or metal clips in your head.
I tested positive for opiates without a prescription, or I'm taking more than 200 mg of morphine daily with a prescription.
See 19 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo 30 1-hour treatment sessions of APT and iTBS, conducted 3 times per week for 10 weeks

10 weeks
30 visits (in-person)

Follow-up

Participants are monitored for changes in PTSD symptoms and adaptability using PCL and MPAI assessments

10 weeks
Assessments at baseline, 5 weeks, 10 weeks, and 20 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • APT
  • iTBS
Trial Overview The study tests the combined effect of attention processing training (APT) with intermittent theta burst stimulation (iTBS), against placebos for each treatment. It aims to assess improvements in attention among those with mTBI plus PTSD and understand changes in their neurocognitive systems.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Active Control
Group I: real APT+ real iTBSExperimental Treatment2 Interventions
Group II: placebo APT+ real iTBSActive Control2 Interventions
Group III: real APT + placebo iTBSActive Control2 Interventions
Group IV: placebo APT+ placebo iTBSActive Control2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials
1,674
Recruited
989,000+

Theresa Pape

Lead Sponsor

Trials
1
Recruited
200+

Published Research Related to This Trial

In a study of 26 patients with bipolar depression, active intermittent theta burst stimulation (iTBS) showed a high response rate of 72% and a remission rate of 42%, indicating its potential efficacy in treating this condition.
No adverse events were reported, demonstrating that iTBS is safe and well-tolerated, but further research with larger sample sizes is needed to confirm its superiority over sham treatment.
Twice-daily neuronavigated intermittent theta burst stimulation for bipolar depression: A Randomized Sham-Controlled Pilot Study.Bulteau, S., Beynel, L., Marendaz, C., et al.[2020]
Intermittent theta-burst stimulation (iTBS) shows promise as a targeted treatment for cognitive and psychosocial deficits following traumatic brain injury (TBI), potentially enhancing recovery when combined with behavioral interventions like cognitive rehabilitation and psychotherapy.
This review suggests that iTBS could lead to consistent functional gains in TBI patients, and future research may explore its application in other complex neuropsychiatric conditions.
rTMS/iTBS and Cognitive Rehabilitation for Deficits Associated With TBI and PTSD: A Theoretical Framework and Review.Lindsey, A., Ellison, RL., Herrold, AA., et al.[2023]
Intermittent Theta Burst Stimulation (iTBS) was well-tolerated by eight Australian veterans with PTSD, with only mild to moderate side effects reported, such as cranial pain and headaches, which were manageable with analgesics.
Participants showed significant reductions in PTSD and depression symptoms after 20 sessions of iTBS, along with improvements in cognitive functions like working memory and processing speed, suggesting that iTBS could be a promising new treatment for veterans with PTSD.
Exploring Theta Burst Stimulation for Post-traumatic Stress Disorder in Australian Veterans-A Pilot Study.Nursey, J., Sbisa, A., Knight, H., et al.[2021]

Citations

SMART accelerates rate of cognitive gains in service ...SMART is an efficient and effective CR protocol for improving higher-order cognitive abilities in ADSMs with mTBI, achieving comparable outcomes to SCORE in 60 ...
Attention Training After Moderate-to-Severe Traumatic ...Overall findings suggest that attentional gains can be made in this sample, irrespective of time since injury, age, and injury severity.
Standardizing Attention Process Training-III for a Multisite ...Attention Process Training-III (APT-III) was selected for its strong evidence base, manualized procedures, and computerized program. However, ...
Cognitive Training for Mild Traumatic Brain Injury and ...This randomized controlled trial examined the effectiveness of a 9-h group cognitive training targeting higher-order functions, Strategic Memory Advanced ...
An Open-Label Feasibility Trial Examining the ...The current study investigated the efficacy of an established cognitive remediation program, Goal Management Training (GMT), in improving cognitive functioning.
A New Mobile App to Train Attention Processes in People With ...This tool can be tested to train attention processes after a neurological insult such as traumatic brain injury.
Attention Process Training in NeurorehabilitationTo evaluate the latest evidence on Attention Process Training (APT) from the past decade across various conditions affecting cognitive function.
Managing Return to Activities | HEADS UPSome policies may require health care professionals to take a training program or provide written clearance as part of the return to play ...
NCT05837676 | Problem-Solving Training for ConcussionAlso called a data safety and monitoring board, or DSMB. Early Phase 1 (formerly listed as Phase 0). A phase of research used to describe exploratory trials ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security